Home – Page 28 – The Cancer Letter

Issue 9 - Mar 1, 2019

TCL45-09 (234 downloads)

ODAC gives thumbs down to single-arm trial of two-drug combination for multiple myeloma
Committee focuses on meaning of equipoise, accelerated approval, confirmatory trials
It’s not just the absence of a randomized trial that prompted the FDA Oncologic Drugs Advisory Committee to recommend against an accelerated approval of the Karyopharm Therapeutics Inc. drug selinexor for late-stage multiple myeloma.
FDA tightens regulation of robotic devices in minimally invasive surgery for cancer
Device manufacturers looking to market surgical tools for use in the prevention or treatment of cancer may now be required to study long-term oncologic endpoints in surgical trials, according to a safety communication published by FDA on Feb. 28.
In Brief
- NCORP networks to take part in NCI’s Moonshot Tissue Procurement Protocol
Conversation with The Cancer Letter
CDC: HPV vaccine dramatically reduced HPV-related cervical precancers over 6 years
The number of cases of HPV+ cervical precancers has dropped by 21 percent from 2008 to 2014, according to a survey by the Centers for Disease Control and Prevention.
Clinical Roundup
- BRACAnalysis CDx test identified patients with pancreatic cancer who benefitted from Olaparib
- PET scans show biomarkers could spare some breast cancer patients from chemotherapy
- Medicaid expansion in Kentucky led to more screening and higher CRC survival
- Study shows annual non-invasive stool test effective for colon cancer screening
- Lab-grown mini tumors could help identify personalized treatments for people with rare cancers
- Inherited mutations may play a role in development of pancreatic cancer
Drugs & Targets
- FDA approves new formulation of Herceptin
- FDA approves Lonsurf with GEJ adenocarcinoma

Issue 8 - Feb 22, 2019

TCL45-08 (235 downloads)

NCI invites scientists to step up competition for $173 million set-aside for commercialization
NCI would like you to know that it has a pot of money for commercialization projects—please apply.
Together, the institute’s Small Business Innovation Research and Small Business Technology Transfer programs are giving out $173 million in fiscal 2019. At NIH, these programs gave out $1.145 billion.
Conversation with The Cancer Letter
Caryn Lerman on leading USC Norris: Team science is where breakthroughs emerge
Caryn Lerman was named director of USC Norris Comprehensive Cancer Center.
When she reports to work at USC on March 15, Lerman will be the only behavioral scientist to lead an NCI-designated cancer center. She also will hold the position of professor of psychiatry and the behavioral sciences at the Keck School of Medicine of USC.
In Brief
- NCI’s Rosenberg to receive Szent-Györgyi prize
- Vale named executive director of HHMI Janelia Research Campus
- Baylor consolidates cancer center clinics on new McNair Campus
- Merck to acquire Immune Design
- Doubrava joins Fox Chase
Funding Opportunities
ASCO invites applications for research based on data from CancerLinQ Discovery
The American Society of Clinical Oncology is inviting applications for research grants for projects that use data from CancerLinQ Discovery, an offering of ASCO’s CancerLinQ initiative, as a source.
Clinical Roundup
- Guidelines recommend genetic testing for all people with breast cancer
- Keytruda + Inlyta reduced risk of death by nearly half compared to sunitinib in RCC
- OS and PFS for Keytruda in hepatocellular carcinoma did not meet statistical significance
- Merck expands immuno-oncology program with three phase III trials in prostate cancer
- Opdivo + Yervoy shows response in pre-treated patients with prostate cancer
- Janssen announces preliminary results from phase II GALAHAD in prostate cancer
- Roswell Park researchers identify protein that contributes to racial disparities in prostate cancer
- AVEO Oncology announces TIVO-3 trial topline results
- SCLC may respond to combination of immunotherapy and DNA damage repair inhibitors
- Study finds melanoma brain metastases immunosuppressive with treatment-resistant metabolism
- Dasatinib enhances response to checkpoint inhibitors, study finds
- Integrating heart disease and cancer care could reduce overall health care costs
- CASSINI Trial publishes data on preventing blood clots in cancer patients
Drugs & Targets
- FDA approves Keytruda for adjuvant treatment of melanoma
- FDA accepts IND for TR1801-ADC, an ADC targeting cMet positive solid tumors
- FDA grants priority review to Merck’s sBLA for Keytruda monotherapy in SCLC
- FDA publishes revised draft guidance for investigational tobacco products

Issue 7 - Feb 15, 2019

TCL45-07 (881 downloads)

Guest Editorial
Making the case to double NIH
The decision to double the budget of the National Institutes of Health should be easy, because it will save lives and save our economy simultaneously. The case for NIH is overwhelming, and there is broad bipartisan congressional support. So why is it so challenging?
NCI Director’s Report
Sharpless: Please stay in oncology, don’t stop sending good research ideas to NCI
The mathematical concepts underlying the challenge NCI is facing today aren’t difficult to grasp. In fact, a 14-year-old in an algebra class should be able to get it, NCI Director Ned Sharpless said to the National Cancer Advisory Board Feb. 12.
In Brief
- Caryn Lerman named director at USC Norris Comprehensive Cancer Center
- St. Baldrick’s and ACS form partnership focused on pediatric cancers
- Report calls on US to accelerate the elimination of cervical cancer worldwide
Clinical Roundup
- Keytruda + Inlyta improves OS, PFS and ORR vs. Sunitinib in RCC
- Immunotherapy appears better than chemotherapy for skin cancer
- Group of lymph nodes to determine prognosis for mesothelioma
- Phase III ARCHES trial shows Xtandi improved PFS in prostate cancer
- Opdivo + Yervoy shows continued survival benefit in RCC
- Immunotherapy effective in recurrent glioblastoma
- Black-white cancer mortality gap nearly eliminated in some age groups
- Report calls on US to accelerate the elimination of cervical cancer worldwide
Drugs & Targets
- European Commission approves Sprycel + chemo for pediatric
- FDA grants Priority Review for Keytruda in head and neck squamous cell carcinoma
- FDA accepts sBLA and grants Priority Review for Bavencio + Inlyta in RCC

Page 28 of 114« First «...10...24 25 26 272829 30 31 32 33...40 50 60 70 80 90 100 110...»Last »